8-K: Aethlon Medical Issues New Warrants Following Exercise of Existing Warrants, Securing $2.3 Million

Aethlon Medical secures $2.3 million through warrant inducement agreement, issuing new warrants and adjusting exercise prices.

Summary

• Aethlon Medical, Inc. entered into a warrant inducement agreement on March 16, 2025, with an accredited and institutional holder of its existing Class A and Class B warrants.
• The agreement incentivized the holder to exercise existing warrants, resulting in gross proceeds of approximately $2.316 million for the company.
• In exchange for exercising the existing warrants, the holder received new unregistered Common Stock Purchase Warrants to purchase up to 200% of the number of warrant shares issued pursuant to the exercise of the existing warrants.
• The exercise price for the new warrants is $0.3736 per share, subject to adjustment, and they are exercisable six months from the issuance date, expiring five and a half years from the issuance date.
• As a result of the warrant exercise, Aethlon Medical issued 6,200,000 shares of its common stock.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• Aethlon Medical agreed to file a resale registration statement for the shares underlying the new warrants within 90 days and to use commercially reasonable efforts to have it declared effective within 150 days.
• The company agreed not to issue further common stock or equivalents for 60 days after the closing date, with limited exceptions.
• Maxim Group, LLC, acted as the placement agent and received a cash fee of 6.0% of the gross proceeds and $15,000 for legal fees and expenses.
• Stockholder approval is required to retroactively approve the Reset of the Exercise Price provision of the New Warrants.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. The company secured funding, but the issuance of new warrants could lead to dilution.

Positives

• Aethlon Medical secured $2.316 million in gross proceeds, strengthening its working capital.
• The warrant inducement agreement led to the exercise of existing warrants, converting them into equity.
• The company has a period of 60 days with limited exceptions to issue further common stock or equivalents, potentially stabilizing the stock price.
• The shares underlying the Existing Warrants have all been registered on Form S-1 registration statement (Registration Number 333-278188).

Negatives

• The issuance of new warrants could lead to future dilution of existing shareholders' equity.
• The company is obligated to pay liquidated damages if the resale registration statement is not filed or made effective within the specified timeframes.
• Aethlon Medical is restricted from issuing additional common stock or equivalents for 60 days, which may limit flexibility in raising capital.
• The company agreed to pay its placement agent, Maxim Group, LLC (the Agent) the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated by the Agreement, and (ii) legal fees and out-of-pocket expenses of $15,000.

Risks

• Failure to obtain stockholder approval for the Reset of the Exercise Price provision of the New Warrants could lead to complications.
• The company may face challenges in meeting the deadlines for filing and effectiveness of the resale registration statement, potentially incurring liquidated damages.
• The new warrants are unregistered, limiting their transferability and potentially affecting their value.
• The company's reliance on warrant exercises for funding may indicate a need for additional capital in the future.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes and must file a resale registration statement for the new warrant shares.

Industry Context

Warrant inducement agreements are a common tool used by companies to raise capital and strengthen their balance sheets. The success of this strategy depends on market conditions and investor sentiment.

Comparison to Industry Standards

• The 6% placement agent fee is within the typical range for similar transactions.
• The warrant exercise price of $0.3736 is reflective of the company's current stock price.
• The terms of the new warrants, including the exercise price and expiration date, are standard for this type of financing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new warrants and common stock.
• The company's employees and customers may benefit from the increased working capital.
• The company's creditors may benefit from the improved financial position.

Next Steps

• File a resale registration statement for the shares underlying the new warrants within 90 days.
• Obtain stockholder approval for the Reset of the Exercise Price provision of the New Warrants.
• Use the net proceeds for working capital and general corporate purposes.

Key Dates